# Supplementary Material

## Framework - Merlin Framework (left) Adaptation for the Belgian Context (right)

| ***Nr.*** | ***Merlin et al. Criteria*** | ***RIZIV-INAMI Criteria*** |
| --- | --- | --- |
| **Context for the submission – Section A** | | |
| 1 | (T) Who is the test sponsor? | *Removed from Analysis* |
| 15 | (T) How is it suggested that the test will be  offered in Australia? | (T) How is it suggested that the test will be  offered in Belgium? |
| **Clinical benefit of the pair of co‐dependent technologies in terms of patient health outcomes – SECTION B** | | |
| 24 | (O) Is the direct evidence provided applicable  to the requested MBS and PBS populations? | (O) Is the direct evidence provided applicable to the Belgian subgroups? |
| 30 | (T) Is the evidence of test accuracy and safety applicable to the requested MBS and PBS populations? | (T) Is the evidence of test accuracy and safety applicable to the requested Belgian population? |
| 39 | (O) Is the evidence supporting the pairing of the co-dependent technologies applicable to the intended MBS and PBS populations? | (O) Is the evidence supporting the pairing of the co-dependent technologies applicable to the intended Belgian population? |
| **Can the test-drug evidence of effectiveness be translated to an economic model for the Australian clinical setting? - Section C** | | |
| 40 | (T & D) Was translation of trial data to the Australian setting conducted appropriately? | (T & D) Was translation of trial data to the Belgium setting conducted appropriately?  According to: “Cleemput I, Neyt M, Van De Sande S, Thiry N. Belgische richtlijnen voor economische evaluaties en budget impact analyses: tweede editie. Health Technology Assessment (HTA). Brussel: Federaal Kenniscentrum voor de Gezondheidszorg (KCE); 2012. KCE Report 183A. D/2012/10.273/52” |
| 41 | (T & D) What are the proposed translation analyses? | Included, Cleemput et al. |
| 42 | (If relevant) (D) How are surrogate outcomes transformed to final patient-relevant outcomes? | Included, Cleemput et al. |
| **Is the proposed use of the pair of co-dependent technologies cost‐effective? SECTION D** | | |
| 71 | (O) Was a scenario analysis provided concerning the option of PBS listing the drug without the biomarker test pre-requisite? | (O) Was a scenario analysis provided concerning the option of listing the drug without the biomarker test pre-requisite? |
| **What is the financial impact of the proposed listing of the pair of co-dependent technologies? - SECTION E** | | |
| 72 | (O) Is a financial impact analysis presented incorporating both MBS and PBS components, with results split by sector (public, private, patient, other)? | (O) Is a financial impact analysis presented incorporating both the test and drug costs. |